CTIS2023-509270-37-00进行中（未招募）1 期
A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL) - LOXO-BTK-18001 BRUI
oxo Oncology Inc.0 个研究点目标入组 938 人开始时间: 2024年4月30日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 938
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Phase 1 dose escalation and expansion and Phase 2: Inclusion criteria / 1: Phase 1: Histologically confirmed B-cell malignancy (e.g., CLL/SLL, WM, NHL) failed or intolerant to either = 2 prior standard-of-care regimens given in combination or sequentially OR have received 1 prior BTK-containing regimen when a BTK inhibitor is approved as first line therapy., Phase 2 Inclusion criteria All patients must have disease requiring treatment. For CLL/SLL patients, indications for treatment are defined by IWCLL. Patients with NHL with measurable disease who will be evaluated by Lugano criteria must have at least 1 site of radiographically assessable disease (i.e., lymph node longest diameter [LDi] > 1.5 cm not necessary for disease assessable by positron emission tomography (PET)/computerized tomography (CT), extra nodal site > 1.0 cm in LDi). Patients with WM must have measurable disease, defined as the presence of serum immunoglobulin M (IgM) with a minimum IgM level of > 2 × the upper limit of normal (ULN) based on local laboratory testing. Patients with nonmeasurable disease are eligible and will be assigned to Cohort 7., Phase 1b pirtobrutinib combinations Inclusion criteria 1/ Arm A: (venetoclax + pirtobrutinib): Histologically confirmed relapsed/recurrent CLL/SLL in whom venetoclax is appropriate standard salvage treatment; no prior venetoclax is permitted., Phase 1b pirtobrutinib combinations Inclusion criteria 1/ Arm B: (rituximab + venetoclax + pirtobrutinib [VR-305]): Histologically confirmed relapsed/refractory (r/r) CLL/SLL in whom venetoclax + rituximab is appropriate standard salvage treatment; prior anti-CD20 therapy is allowed; no prior venetoclax is permitted., Phase 1b pirtobrutinib combinations Inclusion criteria 2 Adequate hematologic status, defined as the following within 7 days of C1D1 before treatment; see also Exclusion Criterion 8: a. ANC = 0.75× 109/L; the patient may enroll if there is documented bone marrow involvement considered to impair hematopoiesis. b. Platelet count = 50 × 109/L not requiring transfusion support; the patient may enroll below this threshold if there is documented bone marrow involvement considered to impair hematopoiesis. c. Hb = 8 g/dL not requiring transfusion support or growth factors; the patient may enroll below this threshold if there is documented bone marrow involvement considered to impair hematopoiesis. d. Patient must be responsive to transfusion support if given for thrombocytopenia or anemia. Patients known to be refractory where increase in platelets to transfusion support is sustained for < 24 hours are not eligible., Inclusion Criteria for All Patients 1 Eastern Cooperative Oncology Group (ECOG) 0 to 2, Inclusion Criteria for All Patients 2 At least 18 years of age, Inclusion Criteria for All Patients 3 Confirmation of availability of tumor sample obtained after most recent treatment as described in Section 7.4 of the protocol, Inclusion Criteria for All Patients 4 Adequate coagulation, defined as activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT) and prothrombin time (PT) or (international normalized ratio [INR]) not greater than 1.5 × ULN, Inclusion Criteria for All Patients 5 Adequate hepatic function, defined as: a. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) = 2.5 × ULN or = 5 × ULN with documented liver metastases b. Total bilirubin = 1.5 × ULN or = 3 × ULN with documented liver metastases and/or Gilbert’s Dis
排除标准
- •Investigational agent or anticancer therapy within 5 half-lives or 14 days, whichever is shorter, prior to planned start of specified study therapy except antineoplastic and immunosuppressant monoclonal antibody treatment must be discontinued a minimum of 4 weeks prior to the first dose of pirtobrutinib. In addition, no concurrent systemic anticancer therapy is permitted. a. Continuation of certain standard-of-care anticancer therapies, including hormonal therapy for breast and prostate cancer, is allowed, provided they are not on the list of prohibited concomitant medications. Refer to Section 6.4.2 for allowed and Section 6.4.3 for prohibited medications., Prolongation of the QT interval corrected for heart rate (QTcF) > 470 msec on at least 2/3 consecutive electrocardiograms (ECGs), and mean QTcF > 470 msec on all 3 ECGs during Screening. QTcF is calculated using Fridericia’s Formula: QTcF = QT/(RR0.33). a. Correction of suspected drug-induced QTcF prolongation can be attempted at the Investigator’s discretion and only if clinically safe to do so with either discontinuation of the offending drug or switch to another drug not known to be associated with QTcF prolongation., Patients who experienced a major bleeding event with a BTK inhibitor NOTE: Major bleeding is defined as bleeding having one or more of the following features: potentially life-threatening bleeding with signs or symptoms of hemodynamic compromise; bleeding associated with a decrease in the hemoglobin level of at least 2 g per deciliter; or bleeding in a critical area or organ (e.g., retroperitoneal, intraarticular, pericardial, epidural, or intracranial bleeding or intramuscular bleeding with compartment syndrome)., Active uncontrolled systemic bacterial, viral, fungal, or parasitic infection (except for fungal nail infection), or other clinically significant active disease process which, in the opinion of the Investigator and the Sponsor, makes it undesirable for the patient to participate in the trial. Screening for chronic conditions is not required., Patients who have tested positive for human immunodeficiency virus (HIV) are excluded due to potential drug-drug interactions between antiretroviral medications and pirtobrutinib and risk of opportunistic infections with both HIV and irreversible BTK inhibitors. For patients with unknown HIV status, HIV testing will be performed at Screening and result should be negative for enrollment., Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption of any of the orally administered study drugs, Current treatment with certain strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers (refer to Appendix I) and/or strong p-glycoprotein (P-gp) inhibitors (Phase 1b only) (refer to Appendix J), Pregnancy or lactation, Active second malignancy unless in remission and with life expectancy > 2 years. Refer to Protocol Exclusion Criteria (Section 4.2) for examples of allowed second malignancies., For patients enrolled to Phase 1b Arm A or B: Patients with prior treatment with venetoclax or other BCL-2 inhibitors, Prior treatment with pirtobrutinib, Major surgery within 4 weeks prior to planned start of specified study therapy, Patients with the following are excluded: • Known hypersensitivity to any component or excipient of pirtobrutinib • For patients enrolled to Phase 1b Arm B, prior significant hypersensitivity, allergy, or anaphylactic reaction to rituximab/
研究者
相似试验
进行中（未招募）
1 期
An Early Phase Study with the Drug LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Non-Hodgkin Lymphoma (NHL)MedDRA version: 20.1 Level: LLT Classification code 10008976 Term: Chronic lymphocytic leukemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10003908 Term: B-cell small lymphocytic lymphoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10029547 Term: Non-Hodgkin's lymphoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003340-24-FRoxo Oncology, Inc.190
进行中（未招募）
1 期
An Early Phase Study with the Drug LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Non-Hodgkin Lymphoma (NHL)MedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10003908Term: B-cell small lymphocytic lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 22.0Level: PTClassification code 10029547Term: Non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003340-24-ITOXO ONCOLOGY INCORPORATED295
进行中（未招募）
1 期
An Early Phase Study with the Drug LOXO-305 in Patients with PreviouslyTreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL) or Non-Hodgkin Lymphoma (NHL)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Non-Hodgkin Lymphoma (NHL)MedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10003908Term: B-cell small lymphocytic lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 22.0Level: PTClassification code 10029547Term: Non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003340-24-GBoxo Oncology, Inc.850
进行中（未招募）
1 期
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)JPRN-jRCT2031200245Tsai E. Donald30
进行中（未招募）
1 期
A Phase 1 study on the effects of LOXO-292 (study drug) in patients with advanced solid tumorsDose escalation: Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor refractory to standard of care therapy, or for whom no standard of care therapy is available.Dose expansion: Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor with evidence of a RET gene alteration in tumor and/or blood.MedDRA version: 20.0Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10027105Term: Medullary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000800-59-NLoxo Oncology, Inc.570